Retatrutide is a novel triple agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors. This innovative mechanism allows it to exert powerful metabolic effects by combining the actions of three key gut hormones involved in glucose and energy regulation. By activating the GLP-1 receptor, Retatrutide enhances insulin secretion and suppresses appetite. Through the GIP receptor, it further promotes insulin release and supports fat metabolism. Meanwhile, stimulation of the glucagon receptor increases energy expenditure and promotes weight loss. This synergistic effect results in significant improvements in both blood sugar control and body weight reduction. In clinical trials, Retatrutide has shown remarkable efficacy, with participants experiencing substantial weight loss—up to 24% of body weight—over the course of 48 weeks. These outcomes suggest that Retatrutide could represent a major advancement in the treatment of obesity and type 2 diabetes.
| Product Name | Retatrutide Peptide |
| Shelf Life | 2 Years |
| Form | Peptide |
| Indication | Weight Loss |
| Dosage | 1mg~12mg/week |
| Active Ingredient | Retatrutide |
| Storage Conditions | Store At 2-25°C |
| Packaging | 10mg/vial, 15mg/vial, 20mg/vial, 30mg/vial, 40mg/vial |
1. For blood sugar control in adults with type 2 diabetes.
2. Improve long-term weight management in overweight patients with adult obesity or with at least one weight-related comorbidity.
For high value products, please select air shipping and express delivery for safety.
